FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
Reply |
|
Thread Tools | Display Modes |
02-01-2010, 09:22 AM | #1 | |||
|
||||
Magnate
|
Interim positive data from Phase IIa clinical study of Synosia Therapeutics' SYN115 announced
The Medical News, February 2010 01:39 http://www.news-medical.net/news/201...announced.aspx Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. “We have successfully established that SYN115 is getting into the brain, changing the activity of relevant regions of the brain, and we now have a better understanding of the doses that are likely to be therapeutically useful. Those were our objectives in undertaking the study.”The Phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 Parkinson’s patients using doses up to 120mg/day for one week. The effects of SYN-115 as an add-on therapy to a stable dose of levodopa was assessed using a number of techniques, including functional Magnetic Resonance Imaging (fMRI), clinical ratings such as the Unified Parkinson’s Disease Rating Scale and various cognitive tests.
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
Reply With Quote |
"Thanks for this!" says: | RLSmi (02-01-2010) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
May2009: Ceregene Presents Additional Clinical Data Phase 2 Trial of CERE-120 for PD | Parkinson's Disease | |||
CERE-120 /May2009/ Clinical Data from Phase 2 Trial of CERE-120 for PD | Parkinson's Disease Clinical Trials | |||
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for | ALS News & Research | |||
Positive Results of Phase 3 Study of Fampridine-SR on walking | Multiple Sclerosis |